SCHEMBL4263364

SCHEMBL4263364

CCOC(=O)CC(=O)c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.56
RAB9A P51151 3/20 0.50
ERCC5 P28715 1/20 0.49
FEN1 P39748 1/20 0.49
MAPT P10636 3/20 0.48
LMNA P02545 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
KDM4E B2RXH2 2/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 2/20 0.47
CXCR3 P49682 1/20 0.46
TSHR P16473 3/20 0.46
HTT P42858 1/20 0.46
GSK3B P49841 2/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276803 0.95 SMN1; SMN2 (0.61) SMN1; SMN2RAB9AERCC5FEN1MAPT
SCHEMBL11087771 0.88 MMP1 (0.55) SMN1; SMN2ERCC5FEN1MAPTLMNA
SCHEMBL7409439 0.87 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AERCC5FEN1MAPT
SCHEMBL11834763 0.86 KMT2A (0.60) SMN1; SMN2RAB9AMAPTLMNAL3MBTL1
SCHEMBL4270804 0.85 MAPT (0.61) SMN1; SMN2RAB9AERCC5FEN1MAPT
SCHEMBL6138451 0.83 KMT2A (0.51) SMN1; SMN2RAB9AMAPTLMNAL3MBTL1
SCHEMBL9859579 0.82 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AERCC5FEN1MAPT
SCHEMBL3167665 0.82 MAOB (0.62) SMN1; SMN2RAB9AMAPTLMNAL3MBTL1
SCHEMBL572 0.81 KMT2A (0.58) RAB9AMAPTLMNAL3MBTL1KDM4E
SCHEMBL10596300 0.80 KMT2A (0.65) SMN1; SMN2RAB9AMAPTLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
EP-1730130-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2006-12-13 EP disclosed
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed
WO-2005085221-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity MCHR2, MCHR1, NPY1R SMN1; SMN2 2654/4885RAB9A 2829/4885ERCC5 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.